Please login to the form below

Not currently logged in
Email:
Password:

eculizumab

This page shows the latest eculizumab news and features for those working in and with pharma, biotech and healthcare.

Rivals rise as safety issue mars Pfizer’s DMD gene therapy trial

Rivals rise as safety issue mars Pfizer’s DMD gene therapy trial

This involved an acute kidney injury, haemolysis, and reduced platelet count and required hospitalisation in intensive care, dialysis and treatment with Alexion’s kidney drug Soliris (eculizumab).

Latest news

More from news
Approximately 4 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Alexion is bracing for the patent expiry of its blockbuster Soliris (eculizumab), used to treat paroxysmal nocturnal haemoglobinuria (PNH) and myasthenia gravis, which hit revenues of around $3bn in 2018.

  • NICE and ‘ultra orphans’ NICE and ‘ultra orphans’

    highly specialised technologies programme was Soliris (eculizumab).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics